Table 6.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1993 to 2002

Recipients with Pancreas Transplant Alone (PTA) Transplants

		Year of Transplant
		1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants		54	40	41	53	79	88	137	135	165	177
Tx with Antirejection Treatments		18	17	24	22	22	21	32	28	20	33
Antibodies	Category Usage	72.2%	70.6%	54.2%	54.5%	68.2%	52.4%	84.4%	89.3%	65.0%	63.6%
	ALG	33.3%	17.6%	4.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG/NRATG/NRATS	0.0%	5.9%	4.2%	40.9%	18.2%	9.5%	0.0%	0.0%	5.0%	0.0%
	OKT3	55.6%	64.7%	50.0%	40.9%	59.1%	47.6%	68.8%	53.6%	30.0%	42.4%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	9.5%	37.5%	53.6%	40.0%	33.3%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	12.5%	3.6%	5.0%	3.0%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.1%	3.6%	5.0%	0.0%
	Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	9.1%
Corticosteroids	Category Usage	27.8%	52.9%	50.0%	90.9%	63.6%	71.4%	75.0%	78.6%	90.0%	81.8%
	Steroids	27.8%	52.9%	50.0%	90.9%	63.6%	71.4%	75.0%	78.6%	90.0%	81.8%
Antimetabolites	Category Usage	0.0%	0.0%	0.0%	0.0%	4.5%	0.0%	0.0%	0.0%	0.0%	0.0%
	Methotrexate	0.0%	0.0%	0.0%	0.0%	4.5%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 3, 2004.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.